[go: up one dir, main page]

AU2002339230A1 - A susceptibility gene for late-onset idiopathic parkinson's disease - Google Patents

A susceptibility gene for late-onset idiopathic parkinson's disease

Info

Publication number
AU2002339230A1
AU2002339230A1 AU2002339230A AU2002339230A AU2002339230A1 AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1 AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1
Authority
AU
Australia
Prior art keywords
late
disease
susceptibility gene
idiopathic parkinson
onset idiopathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339230A
Inventor
Andrew A. Hicks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of AU2002339230A1 publication Critical patent/AU2002339230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2002339230A 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease Abandoned AU2002339230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36322002P 2002-03-08 2002-03-08
US60/363,220 2002-03-08
PCT/IB2002/004276 WO2003076658A2 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Publications (1)

Publication Number Publication Date
AU2002339230A1 true AU2002339230A1 (en) 2003-09-22

Family

ID=27805269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339230A Abandoned AU2002339230A1 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Country Status (2)

Country Link
AU (1) AU2002339230A1 (en)
WO (1) WO2003076658A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease
DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
JP5282228B2 (en) * 2005-10-21 2013-09-04 株式会社ファンケル Atopic dermatitis marker and its application technology
EP3255049A1 (en) 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
PE20190395A1 (en) 2016-06-16 2019-03-13 Denali Therapeutics Inc PYRIMIDIN-2-ILAMINO-1H-PYRAZOLES AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402735A1 (en) * 2000-03-13 2001-10-04 Incyte Genomics, Inc. Human transcription factors
AU2001264950A1 (en) * 2000-05-26 2001-12-11 Duke University Methods of screening for parkinson's disease

Also Published As

Publication number Publication date
WO2003076658A3 (en) 2003-12-31
WO2003076658A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
GB0318428D0 (en) Gene drivers
AU2003231509A1 (en) Compound exhibiting pgd 2 receptor antagonism
EP1580270A4 (en) Gene for increasing crop yield and use thereof
AU2002339230A1 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
AU2002319717A1 (en) Mutant nurr1 gene in parkinson's disease
AU2003272608A1 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003285346A1 (en) Regulatory elements in the 5' region of the vr1 gene
AU2003285069A8 (en) Type 2 diabetes mellitus genes
AU2003264845A1 (en) Parkinson's disease susceptibility haplotype as a tool for genetic screening
AU2003257651A1 (en) 4'-thionucleotide
AU2002341044A1 (en) Methods for detecting parkinson's disease
AU2003251962A1 (en) Screening for alzheimer's disease
AU2003224826A1 (en) Endohedral metallofullerene contrast agents
EP1591531A4 (en) Process for acyl-transfer enzyme reactions with acyl- coenzyme a
AU2003268519A1 (en) Type 2 diabetes susceptibility genes
GB0410101D0 (en) Parkinson's disease
AU2003294705A8 (en) Ntsm gene
AU2003284640A1 (en) Type 2 diabetes-associated gene
GB0202087D0 (en) Non-drain 'T' connector
AUPS037102A0 (en) A novel gene
AU2002331051A1 (en) An animal model for parkinson's disease
PL356071A1 (en) Mutbar 1 gene
EP1514924A4 (en) Novel acylase gene
AU2003267384A1 (en) Bhyd gene

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase